Results 91 to 100 of about 684,663 (243)
Vurdering av tester for PD-L1 ved urotelialt karsinom: en forenklet metodevurdering
, 2021 Hovedbudskap: Programmed cell death ligand 1 (PD-L1) på tumorceller kan binde til Programmed cell death protein 1 på immunceller og hindre disse i å bekjempe og nøytralisere kreftsvulster.
Brurberg, Kjetil Gundro +2 more
core
Immune Checkpoint Inhibitor–Related Myositis and Associated Triad Overlap Syndrome
Arthritis Care &Research, EarlyView.Objective Immune checkpoint inhibitor (ICI) myositis is a rare but a highly morbid condition, particularly with the ICI myositis triad syndrome of myositis, myocarditis, and myasthenia gravis. We report the clinical characteristics of ICI myositis and all‐cause mortality in these patients.
Selene Rubino +9 more
wiley +1 more source
The Prognostic and Therapeutic Value of PD-L1 in Glioma
Frontiers in Pharmacology, 2019 Glioma is the most common type of primary brain tumors. After standard treatment regimen (surgical section, radiotherapy and chemotherapy), the average survival time remains merely around 14 months for glioblastoma (grade IV glioma).
Ruo Qiao Chen +6 more
doaj +1 more source
Cancer Medicine, 2023 Background Anti‐PD1/PD‐L1 antibody plus human epidermal growth factor receptor 2 (HER2) antibody and chemotherapy have become the new first‐line therapy for HER2 overexpression‐positive advanced gastric cancers (GC), suggesting that HER2 and PD‐L1 play a
Xiaoqian Jing +11 more
doaj +1 more source
Advanced Functional Materials, EarlyView.A swelling‐programmed micropatterned hydrogel guides adherent cells through a controlled transition from cell–matrix anchoring to cadherin‐mediated cell–cell compaction, enabling rapid assembly of high‐viability spheroids with defined size and morphology.
Han Gyeol Nam +8 more
wiley +1 more source
Molecular CancerBackground The PD-L1/PD-1 pathway is crucial for immune regulation and has become a target in cancer immunotherapy. However, in order to improve patient selection for immune checkpoint blockade (ICB) therapies, better selection criteria are needed.
Bar Kaufman +13 more
doaj +1 more source
PD-L1 expression U87MG and LN229.wsp
, 2022 PD-L1 expression of U87MG and LN229 cells.
Moritz Klawitter (13177230)
core +1 more source
Ion‐Reconfigurable “N”‐Shaped Antiambipolar Behavior in Organic Electrochemical Transistors
Advanced Materials, EarlyView.A unique N‐shaped negative differential transconductance (NDT) characteristics is demonstrated in single‐polymer organic electrochemical transistors through a sequential doping–redox–doping process driven by iodide ions. This redox‐driven mechanism enables low‐voltage, ion‐controlled reconfigurability and tunable current modulation, allowing seamless ...
Debdatta Panigrahi +11 more
wiley +1 more source
Light-Activated Azobenzene Peptide Inhibitor of the PD-1/PD-L1 Interaction
Inhibiting the protein-protein interaction between programmed cell death 1 (PD-1) and its ligand programmed cell death ligand 1 (PD-L1) has become a focal point in immunotherapy for cancer treatments.
Deanne, Hayward +4 more
core +1 more source